Vertex Pharmaceuticals (VRTX)

Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.

The stock has fallen from a peak back in April.

The stock has climbed in the double-digits in recent years.

Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) jumped 6.2% in the afternoon session after Morgan Stanley upgraded its rating on the stock to "Overweight" from "Equal-Weight" and increased its price target. The new price target was set at $516, a notable increase from the previous $438. The upgrade reflected the bank's more positive outlook on the potential within Vertex's kidney drug pipeline. The firm specifically highlighted two drug candidates, Pove and Inaxaplin, as key drivers for this optimism. This positive view was formed ahead of the expected release of Phase 3 clinical trial data for these drugs in 2026, suggesting strong confidence in the company's future prospects.

Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday.

Stay updated with the movements of the S&P500 index in the middle of the day on Wednesday. Discover which stocks are leading as top gainers and losers in today's session.

Both can help drive excellent returns for patient, disciplined investors.

These stocks deserve a spot on investors' shopping lists this holiday season.

This company's first product has started to generate revenue.

Vertex (VRTX) Q3 2025 Earnings Call Transcript

Prediction: Vertex will be much larger by the end of the decade.

If you're investing for the next 30 years, don't overlook these top stocks.

Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) jumped 2.7% in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. 

Inflation should have a minimal impact on these companies' financial results. And they also boast excellent growth prospects.

Vertex Pharmaceuticals (VRTX) presents a strong value investment case with a low P/E ratio, robust profitability, a healthy debt-free balance sheet, and accelerating earnings growth.

Boston, MA – November 19, 2025 – Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) experienced a dramatic and immediate market backlash, with its stock plummeting over 51.00% following the announcement of mixed topline results from its pivotal RISE UP Phase 3 trial for mitapivat in sickle cell disease (SCD). While the investigational therapy

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.

These stocks both have advanced in the double-digits in recent months.

It's a good idea to go against the current market sentiment on this one.

The global financial markets are in the midst of a profound transformation, driven by an accelerating wave of technological advancements. From the intricate algorithms of Artificial Intelligence to the nascent power of quantum computing and the burgeoning might of renewable energy, these innovations are not merely incremental improvements; they are

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Vertex Pharmaceuticals offers strong growth, solid profits, and a healthy balance sheet, all at a reasonable valuation compared to its biotech peers.